CD22: A Key Molecule in B Cell Signaling Regulation and Its Applications in Disease Treatment and Biomarker Development

Author: Senior Product Manager of UA Views：95

This article systematically elaborates on the molecular structure and expression patterns of CD22 (Siglec-2) as a member of the immunoglobulin superfamily, analyzes its core function in the negative regulation of B-cell signaling and its phase-specific expression characteristics during B-cell development, explores its potential as a therapeutic target in B-cell malignancies and autoimmune diseases as well as the biomarker potential of soluble CD22, and introduces the detection applications of fluorescently labeled recombinant proteins based on these findings.

Recent Advances
Product Information

Recent Advances

CD22: A Key Molecule in B Cell Signal Regulation and Its Applications in Disease Treatment and Biomarkers

Summary: This article systematically elaborates on the molecular structure and expression patterns of CD22 (Siglec-2) as a member of the immunoglobulin superfamily, analyzes its core function in the negative regulation of B cell signaling and its phase-specific expression during B cell development, explores its therapeutic targeting value in B cell malignancies and autoimmune diseases, and discusses the potential of soluble CD22 as a disease biomarker. Additionally, it introduces the detection applications of fluorescently labeled recombinant proteins.

1. Molecular Classification and Basic Structural Features of CD22.

CD22 is a classic member of the sialic acid-binding immunoglobulin-like lectin (Siglec) family and belongs to the immunoglobulin gene superfamily. As a transmembrane glycoprotein, CD22 exhibits distinct modular structural features: its extracellular domain contains seven immunoglobulin-like domains, with the N-terminal first domain responsible for recognizing and binding sialic acid-containing glycans, mediating cell adhesion and signal interactions; the transmembrane region connects the extracellular domains to the intracellular signal transduction region; the intracellular tail carries three immunoreceptor tyrosine-based inhibitory motifs (ITIMs), which, when phosphorylated, recruit SH2 domain-containing protein tyrosine phosphatases to exert inhibitory signaling.

2. Phase-Specific Expression of CD22 During B Cell Development.

The expression of CD22 follows a highly ordered phase-specific pattern during B cell development. In the earliest stages of B cell differentiation, cytoplasmic CD22 begins to be expressed alongside CD19, appearing earlier than CD20—a temporal feature of significant diagnostic value for identifying early B-lineage malignancies. In most precursor B cells, cytoplasmic CD22 is already positive. As B cells mature, surface CD22 expression emerges before or concurrently with surface IgM and/or IgD expression, indicating CD22's critical regulatory role in B cell antigen receptor maturation. When B cells terminally differentiate into plasma cells, CD22 expression is completely lost. This precise phase-specific expression pattern suggests that CD22 participates in setting signaling thresholds at multiple stages of B cell development.

3. Molecular Mechanisms of CD22 in Negatively Regulating B Cell Receptor Signaling.

CD22 is a crucial negative regulator in the B cell receptor (BCR) signaling pathway, playing an irreplaceable role in establishing the signaling threshold for B cell activation. Upon BCR-antigen binding, Src family kinases (e.g., Lyn) phosphorylate tyrosine residues in CD22's intracellular ITIMs, recruiting the protein tyrosine phosphatase SHP-1. SHP-1 dephosphorylates key kinases (e.g., Syk, Btk, and PI3K) in the BCR signaling pathway, effectively suppressing excessive downstream signaling cascades. Thus, CD22 acts as a "brake" in the B cell signaling network, preventing inappropriate overactivation of B cells in response to self or foreign antigens, and serves as a core regulatory element in maintaining B cell self-tolerance and immune homeostasis.

Notably, CD22 and CD19 form a finely balanced mutual regulatory relationship in B cell signaling—CD19 enhances Lyn kinase activity to modulate CD22 phosphorylation, while CD22 inhibits CD19 phosphorylation via SHP-1. This bidirectional regulation ensures that BCR signaling is sufficiently activated to initiate effective responses while being appropriately restrained to prevent overactivation. Genetic studies have linked CD22 to various autoimmune diseases, suggesting that CD22 deficiency and its associated signaling abnormalities may play a significant role in the pathogenesis of autoimmunity.

4. Targeting CD22 in B Cell Malignancies and Autoimmune Diseases.

CD22 is highly expressed on the surface of most B cell malignancy cells, covering major subtypes of B-lineage malignancies, including acute lymphoblastic leukemia, non-Hodgkin lymphoma, and chronic lymphocytic leukemia. This broad tumor coverage, combined with CD22's absence in plasma cells and minimal expression in non-hematopoietic tissues, provides an ideal tumor-specific window for immunotherapeutic targeting. Currently, CD22-targeted therapies fall into three main categories: monoclonal antibodies, antibody-drug conjugates, and CAR-T cell therapies. In autoimmune diseases, CD22 has been successfully used as a therapeutic target for non-Hodgkin lymphoma, Sjögren's syndrome, and systemic lupus erythematosus, modulating B cell activity to alleviate autoimmune responses.

5. Generation Mechanism and Biomarker Potential of Soluble CD22.

Soluble CD22 (sCD22) is released into body fluids following proteolytic cleavage of the extracellular domain of membrane-bound CD22 and represents the primary circulating form of CD22 biological activity. Serum sCD22 levels correlate closely with B cell activation, making it a dynamic indicator of in vivo B cell activity. Recent studies have linked abnormal sCD22 expression to various disease states: in transplant rejection, sCD22 level changes may reflect B cell-mediated immune responses; in Niemann-Pick disease type C, sCD22 may be associated with immune abnormalities caused by sphingomyelin accumulation; in Alzheimer's disease, sCD22 may participate in central nervous system immune-inflammatory responses; and in Gram-negative bacterial sepsis, sCD22 levels may correlate with infection-induced large-scale B cell activation. These findings highlight sCD22's potential as a biomarker for diverse diseases, warranting further exploration.

6. Conclusion.

As a core negative regulator of B cell signaling, CD22 has evolved into a multifunctional molecule with both therapeutic targeting value and biomarker potential, owing to its phase-specific expression during B cell development, fine-tuning of BCR signaling thresholds, broad coverage in B cell malignancies, and genetic associations with autoimmune diseases. From monoclonal antibodies and antibody-drug conjugates to CAR-T cell therapies, CD22-targeting strategies continue to expand. Meanwhile, abnormal sCD22 expression in various diseases opens new avenues for its use as a liquid biopsy marker. Uni's Alexa Fluor 647-Labeled Siglec-2/CD22 His Tag Protein, Human—with its precise molecular design, native conformation ensured by human expression systems, and excellent far-red optical performance—provides a reliable detection tool for CD22-related receptor-ligand binding analysis, CAR-T cell functional assessment, targeted drug screening, and sCD22 research.

```

This article is reviewed and published by the technical expert team of UA

Disclaimer: This article partially utilizes artificial intelligence assistance in its creation. If any content involves copyright or intellectual property issues, please let us know and we promise to verify and remove it as soon as possible.

Purchase recombinant protein, choose Nanjing UA-Bio

UA protein focuses on providing various protein reagents, raw materials, and services required for drug research and development, cell therapy, gene therapy, and basic scientific research, including drug target proteins, immune checkpoint proteins, cytokines, tool enzymes, customized protein expression, and full-length transmembrane protein development. Youai is committed to providing customers with high-quality products and professional services, and building a High-tech Biological Enterprise with International Competitiveness.

Buy antibodiesFind UA www.ua-bio.com | 15 years of protein development experience

Nanjing UA Biotechnology Co., Ltd. Email：order@ua-bio.com Phone：+86-25-56221161

more products

Product Information

The Last The Next